Imagion Biosystems (IBX.AX) Osake Kurssi

Imagion Biosystems Ltd. engages in the research and development of non-radioactive and safe diagnostic imaging technology. The company is headquartered in Melbourne, Victoria. The company went IPO on 2017-06-22. The Company’s principal activity consists of nanotechnology, biotechnology, cancer diagnostics, and medical imaging using superparamagnetic relaxometry. The firm operates through Research and Development segment. Its MagSense technology is a functional imaging agent for detecting cancers and other critical diseases. MagSense technology uses bio-safe magnetic nanoparticles that are cancer-specific. MagSense nanoparticles are specially formulated as an injectable solution for each type of cancer. MagSense applications include breast cancer, prostate cancer, and ovarian cancer. The firm is conducting a Phase I clinical study of its MagSense HER2 imaging agent. Its PrecisionMRX nanoparticles have been developed for magnetic relaxometry and other demanding biomedical applications. Its PrecisionMRX products include Dextran-Coated, mPEG Coated, Oleic Acid Coated and Carboxylic Acid Functionalized.